Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Mar;100(3):e120-1.
doi: 10.3324/haematol.2014.123232.

Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"

Sung-Hyun Kim  1 , Dong-Wook Kim  2
Affiliations
Comment

Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"

Sung-Hyun Kim et al. Haematologica. 2015 Mar.
No abstract available

Keywords: chronic myeloid leukemia; radotinib.

PubMed Disclaimer

Comment on

References

    1. Kim SH, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014;99(7):1191–1196. - PMC - PubMed
    1. Kim SH, Menon H, Jootar S, et al. Early response of radotinib therapy may predict long-term outcomes in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 TKIs: 24 month update of radotinib phase 2 trial. Haematologica (19th Congress of the European Hematology Association Abstracts). 2014: 284a
    1. Kantarjian HM, Giles FJ, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistant and intolerance. Blood. 2007;110(10):3540–3546. - PubMed
    1. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141–1145. - PMC - PubMed
    1. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303–2309. - PubMed

MeSH terms

Substances